New and emerging targeted treatments in advanced non-small-cell lung cancer

The Lancet

Volumn 388, Issue 10048, 2016, Pages 1012-1024

  Hirsch, Fred R ^a,b   Suda, Kenichi ^a   Wiens, Jacinta ^b   Bunn, Paul A ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b International Association for the Study of Lung Cancer   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; SCATTER FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN;

ADVANCED CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); ESTIMATED GLOMERULAR FILTRATION RATE; GENE; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ROS1 GENE; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; GENE TRANSLOCATION; GENETICS; LUNG NEOPLASMS; MUTATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSLOCATION, GENETIC;

EID: 84989201871     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31473-8     Document Type: Review

References (159)

1. 1 Ciardiello, F, Tortora, G, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7 (2001), 2958–2970.
2. 2 Lynch, TJ, Bell, DW, Sordella, R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004), 2129–2139.
3. 3 Paez, JG, Jänne, PA, Lee, JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
4. 4 Pao, W, Miller, V, Zakowski, M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004), 13306–13311.
5. 5 Kosaka, T, Yatabe, Y, Endoh, H, Kuwano, H, Takahashi, T, Mitsudomi, T, Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64 (2004), 8919–8923.
6. 6 Soda, M, Choi, YL, Enomoto, M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007), 561–566.
7. 7 Rikova, K, Guo, A, Zeng, Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131 (2007), 1190–1203.
8. 8 Shigematsu, H, Takahashi, T, Nomura, M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65 (2005), 1642–1646.
9. 9 Brose, MS, Volpe, P, Feldman, M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62 (2002), 6997–7000.
10. 10 Naoki, K, Chen, TH, Richards, WG, Sugarbaker, DJ, Meyerson, M, Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 62 (2002), 7001–7003.
11. 11 Ma, PC, Jagadeeswaran, R, Jagadeesh, S, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65 (2005), 1479–1488.
12. 12 Onozato, R, Kosaka, T, Kuwano, H, Sekido, Y, Yatabe, Y, Mitsudomi, T, Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 4 (2009), 5–11.
13. 13 Takeuchi, K, Soda, M, Togashi, Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 18 (2012), 378–381.
14. 14 Kohno, T, Ichikawa, H, Totoki, Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18 (2012), 375–377.
15. 15 Lipson, D, Capelletti, M, Yelensky, R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18 (2012), 382–384.
16. 16 Imielinski, M, Berger, AH, Hammerman, PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150 (2012), 1107–1120.
17. 17 Seo, JS, Ju, YS, Lee, WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22 (2012), 2109–2119.
18. 18 Vaishnavi, A, Capelletti, M, Le, AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19 (2013), 1469–1472.
19. 19 Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
20. 20 Dhanasekaran, SM, Balbin, OA, Chen, G, et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun, 5, 2014, 5893.
21. 21 Fernandez-Cuesta, L, Plenker, D, Osada, H, et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 4 (2014), 415–422.
22. 22 Nakaoku, T, Tsuta, K, Ichikawa, H, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res 20 (2014), 3087–3093.
23. 23 Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 (2012), 519–525.
24. 24 Kim, Y, Hammerman, PS, Kim, J, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 32 (2014), 121–128.
25. 25 Rudin, CM, Durinck, S, Stawiski, EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44 (2012), 1111–1116.
26. 26 Peifer, M, Fernández-Cuesta, L, Sos, ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44 (2012), 1104–1110.
27. 27 George, J, Lim, JS, Jang, SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524 (2015), 47–53.
28. 28 Tan, DS, Yom, SS, Tsao, MS, et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016. J Thorac Oncol 11 (2016), 946–963.
29. 29 Matikas, A, Kentepozidis, N, Georgoulias, V, Kotsakis, A, Management of resistance to crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer. Clin Lung Cancer, 2016, 10.1016/j.cllc.2016.05.006 published online June 2.
30. 30 Pirker, R, Pereira, JR, Szczesna, A, et al., the FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373 (2009), 1525–1531.
31. 31 Thatcher, N, Hirsch, FR, Luft, AV, et al., the SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16 (2015), 763–774.
32. 32 Sandler, A, Gray, R, Perry, MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006), 2542–2550.
33. 33 Reck, M, von Pawel, J, Zatloukal, P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27 (2009), 1227–1234.
34. 34 Reck, M, Kaiser, R, Mellemgaard, A, et al., the LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15 (2014), 143–155.
35. 35 Garon, EB, Ciuleanu, TE, Arrieta, O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384 (2014), 665–673.
36. 36 Sacher, AG, Gandhi, L, Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol, 2016, 10.1001/jamaoncol.2016.0639 published online June 16.
37. 37 Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
38. 38 Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
39. 39 Garon, EB, Rizvi, NA, Hui, R, et al., the KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
40. 40 Herbst, RS, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
41. 41 Rizvi, NA, Mazières, J, Planchard, D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16 (2015), 257–265.
42. 42 Tsao, AS, Scagliotti, GV, Bunn, PA Jr, et al. Scientific advances in lung cancer 2015. J Thorac Oncol 11 (2016), 613–638.
43. 43 Kris, MG, Johnson, BE, Berry, LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311 (2014), 1998–2006.
44. 45 Takano, T, Fukui, T, Ohe, Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26 (2008), 5589–5595.
45. 46 Barlesi, F, Mazieres, J, Merlio, JP, et al., the Biomarkers France contributors. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387 (2016), 1415–1426.
46. 47 Maemondo, M, Inoue, A, Kobayashi, K, et al., the North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 (2010), 2380–2388.
47. 48 Mitsudomi, T, Morita, S, Yatabe, Y, et al., the West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11 (2010), 121–128.
48. 49 Zhou, C, Wu, YL, Chen, G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12 (2011), 735–742.
49. 50 Rosell, R, Carcereny, E, Gervais, R, et al., the Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13 (2012), 239–246.
50. 51 Sequist, LV, Yang, JC, Yamamoto, N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31 (2013), 3327–3334.
51. 52 Wu, YL, Zhou, C, Hu, CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15 (2014), 213–222.
52. 53 Yang, JC, Sequist, LV, Geater, SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16 (2015), 830–838.
53. 54 Yang, JC, Wu, YL, Schuler, M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16 (2015), 141–151.
54. 55 Park, K, Tan, EH, O'Byrne, K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17 (2016), 577–589.
55. 56 Wu, YL, Lee, JS, Thongprasert, S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol 14 (2013), 777–786.
56. 57 Seto, T, Kato, T, Nishio, M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15 (2014), 1236–1244.
57. 58 Jia, Y, Juarez, J, Li, J, et al. EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Res 76 (2016), 1591–1602.
58. 59 Suda, K, Mizuuchi, H, Maehara, Y, Mitsudomi, T, Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny. Cancer Metastasis Rev 31 (2012), 807–814.
59. 60 Hata, AN, Niederst, MJ, Archibald, HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 22 (2016), 262–269.
60. 61 Soria, JC, Wu, YL, Nakagawa, K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 16 (2015), 990–998.
61. 62 Suda, K, Mitsudomi, T, Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Arch Toxicol 89 (2015), 1227–1240.
62. 63 Yu, HA, Sima, CS, Huang, J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8 (2013), 346–351.
63. 64 Mitsudomi, T, Suda, K, Yatabe, Y, Surgery for NSCLC in the era of personalized medicine. Nat Rev Clin Oncol 10 (2013), 235–244.
64. 65 Sequist, LV, Waltman, BA, Dias-Santagata, D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 2011, 75ra26.
65. 66 Yu, HA, Arcila, ME, Rekhtman, N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19 (2013), 2240–2247.
66. 67 Jänne, PA, Yang, JC, Kim, DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372 (2015), 1689–1699.
67. 68 Sequist, LV, Rolfe, L, Allen, AR, Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 373 (2015), 578–579.
68. 69 Park, K, Lee, J-S, Lee, KH, et al. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI). J Clin Oncol, 33(suppl 15), 2015, 8084 (abstr).
69. 70 Chih-Hsin Yang, J, Kim, DW, Kim, SW, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol, 34(suppl), 2016, 9002.
70. 71 Oxnard, GR, Thress, KS, Alden, RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol, 2016, 10.1200/JCO.2016.66.7162 published online June 27.
71. 72 Sacher, AG, Paweletz, C, Dahlberg, SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol, 2016, 10.1001/jamaoncol.2016.0173 published online April 7.
72. 73 Wang, S, Cang, S, Liu, D, Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol, 9, 2016, 34.
73. 74 Ramalingam, S, Yang, JC, Lee, CK, et al. LBA1_PR: osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two phase I expansion cohorts. J Thorac Oncol, 11(suppl), 2016, S152.
74. 75 Thress, KS, Paweletz, CP, Felip, E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21 (2015), 560–562.
75. 76 Ercan, D, Choi, HG, Yun, CH, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res 21 (2015), 3913–3923.
76. 77 Jia, Y, Yun, CH, Park, E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534 (2016), 129–132.
77. 78 Engelman, JA, Zejnullahu, K, Mitsudomi, T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043.
78. 79 Takezawa, K, Pirazzoli, V, Arcila, ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2 (2012), 922–933.
79. 80 Zhang, Z, Lee, JC, Lin, L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44 (2012), 852–860.
80. 81 Suda, K, Murakami, I, Sakai, K, et al. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Sci Rep, 5, 2015, 14447.
81. 82 Suda, K, Tomizawa, K, Fujii, M, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6 (2011), 1152–1161.
82. 83 Suda, K, Tomizawa, K, Mitsudomi, T, Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 29 (2010), 49–60.
83. 84 Jänne, PA, Shaw, AT, Pereira, JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14 (2013), 38–47.
84. 85 Lito, P, Solomon, M, Li, LS, Hansen, R, Rosen, N, Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351 (2016), 604–608.
85. 86 Skoulidis, F, Byers, LA, Diao, L, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5 (2015), 860–877.
86. 87 Scholl, C, Fröhling, S, Dunn, IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137 (2009), 821–834.
87. 88 Kitai, H, Ebi, H, Tomida, S, et al. Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS-mutant lung cancer. Cancer Discov 6 (2016), 754–769.
88. 89 Manchado, E, Weissmueller, S, Morris, JP 4th, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534 (2016), 647–651.
89. 90 Tao, Z, Le Blanc, JM, Wang, C, et al. Coadministration of trametinib and palbociclib radiosensitizes KRAS-mutant non-small cell lung cancers in vitro and in vivo. Clin Cancer Res 22 (2016), 122–133.
90. 91 Dietlein, F, Kalb, B, Jokic, M, et al. A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell 162 (2015), 146–159.
91. 92 Takeuchi, K, Choi, YL, Togashi, Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15 (2009), 3143–3149.
92. 93 Togashi, Y, Soda, M, Sakata, S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One, 7, 2012, e31323.
93. 94 Shaw, AT, Kim, DW, Nakagawa, K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 (2013), 2385–2394.
94. 95 Solomon, BJ, Mok, T, Kim, DW, et al., the PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 (2014), 2167–2177.
95. 96 Kim, DW, Mehra, R, Tan, DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 17 (2016), 452–463.
96. 97 Mok, T, Spigel, D, Felip, E, et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol, 33(suppl), 2015, 8059 (abstr).
97. 98 Felip, E, Orlov, S, Park, K, et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naive adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol, 33(suppl), 2015, 8060 (abstr).
98. 99 Ou, SH, Ahn, JS, De Petris, L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34 (2016), 661–668.
99. 100 Nokihara, H, Hida, T, Kondo, M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study. J Clin Oncol, 34(suppl 15), 2016, 9008 (abstr).
100. 101 Seto, T, Kiura, K, Nishio, M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol 14 (2013), 590–598.
101. 102 Langer, CJ, Gettinger, SN, Bazhenova, L, et al. Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): phase (ph) 1/2 trial results. J Clin Oncol, 34(suppl 15), 2016, 9057 (abstr).
102. 103 Shaw, AT, Bauer, TM, Felip, E, et al. Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. J Clin Oncol, 33(suppl), 2015, 8018 (abstr).
103. 104 Solomon, BJ, Bauer, TM, Felip, E, et al. Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). J Clin Oncol, 34(suppl 15), 2016, 9009 (abstr).
104. 105 Horn, L, Infante, JR, Blumenschein, GR, et al. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol, 32, 2014, 8030 (abstr).
105. 106 Shaw, AT, Gandhi, L, Gadgeel, S, et al., the study investigators. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17 (2016), 234–242.
106. 107 Rosell, R, Gettinger, SN, Bazhenova, LA, et al. 1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial. J Thorac Oncol, 11(suppl), 2016, S114.
107. 108 Zou, HY, Li, Q, Engstrom, LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA 112 (2015), 3493–3498.
108. 109 Takeuchi, K, Togashi, Y, Kamihara, Y, et al. Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Ann Oncol 27 (2016), 185–192.
109. 110 Hrustanovic, G, Olivas, V, Pazarentzos, E, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med 21 (2015), 1038–1047.
110. 111 Drilon, A, Wang, L, Hasanovic, A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 3 (2013), 630–635.
111. 112 Seto, T, Yoh, K, Satouchi, M, et al. A phase II open-label sigle-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study. J Clin Oncol, 34(suppl), 2016, 9012 (abstr).
112. 113 Lee, SH, Lee, JK, Ahn, MJ, et al. A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. J Clin Oncol, 34(suppl), 2016, 9013 (abstr).
113. 114 Gautschi, O, Wolf, J, Milla, J, et al. Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. J Clin Oncol, 34(suppl), 2016, 9014 (abstr).
114. 115 Cascone, T, Subbiah, V, Hess, KR, et al. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. J Clin Oncol, 34(suppl), 2016, 9069 (abstr).
115. V600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17 (2016), 894–993.
116. 117 Kris, MG, Camidge, DR, Giaccone, G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 26 (2015), 1421–1427.
117. 118 Gandhi, L, Bahleda, R, Tolaney, SM, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 32 (2014), 68–75.
118. 119 Camidge, DR, Ou, SHI, Shapiro, G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol, 32(suppl 5), 2014, 8001 (abstr).
119. 120 Drilon, AE, Camidge, DR, Ou, SHI, et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). J Clin Oncol, 34(suppl), 2016, 108 (abstr).
120. 121 Redig, AJ, Jänne, PA, Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 33 (2015), 975–977.
121. 122 Zhu, VW, Upadhyay, D, Schrock, AB, Gowen, K, Ali, SM, Ou, SH, TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. Lung Cancer 97 (2016), 48–50.
122. 123 Shaw, AT, Ou, SH, Bang, YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371 (2014), 1963–1971.
123. 124 Mazières, J, Zalcman, G, Crinò, L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33 (2015), 992–999.
124. 125 Subbiah, V, Hong, DS, Meric-Bernstam, F, Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: bench to bedside report. Proc Natl Acad Sci USA 113 (2016), E1419–E1420.
125. 126 Wang, R, Hu, H, Pan, Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30 (2012), 4352–4359.
126. 127 Paik, PK, Arcila, ME, Fara, M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29 (2011), 2046–2051.
127. 128 Kinno, T, Tsuta, K, Shiraishi, K, et al. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol 25 (2014), 138–142.
128. 129 Litvak, AM, Paik, PK, Woo, KM, et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol 9 (2014), 1669–1674.
129. 130 Hyman, DM, Puzanov, I, Subbiah, V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373 (2015), 726–736.
130. 131 Tomizawa, K, Suda, K, Onozato, R, et al. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer 74 (2011), 139–144.
131. 132 Mazières, J, Peters, S, Lepage, B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31 (2013), 1997–2003.
132. 133 De Grève, J, Teugels, E, Geers, C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76 (2012), 123–127.
133. 134 Farago, AF, Le, LP, Zheng, Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol 10 (2015), 1670–1674.
134. 135 Awad, MM, Impaired c-Met receptor degradation mediated by MET exon 14 mutations in non-small-cell lung cancer. J Clin Oncol 34 (2016), 879–881.
135. 136 Van Der Steen, N, Giovannetti, E, Pauwels, P, et al. cMET exon 14 skipping: from the structure to the clinic. J Thorac Oncol, 2016, 10.1016/j.jtho.2016.05.005 published online May 17.
136. 137 Ou, SH, Kwak, EL, Siwak-Tapp, C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6 (2011), 942–946.
137. 138 Paik, PK, Drilon, AE, Yu, HA, et al. Response to crizotinib and cabozantinib in stage IV lung adenocarcinoma patients with mutations that cause MET exon 14 skipping. J Clin Oncol, 33(suppl), 2015, 8021 (abstr).
138. 139 Weiss, J, Sos, ML, Seidel, D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med, 2, 2010, 62ra93.
139. 140 Kim, HR, Kim, DJ, Kang, DR, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 31 (2013), 731–737.
140. 141 Hammerman, PS, Sos, ML, Ramos, AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1 (2011), 78–89.
141. 142 Justilien, V, Walsh, MP, Ali, SA, Thompson, EA, Murray, NR, Fields, AP, The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 25 (2014), 139–151.
142. 143 Hirsch, FR, Jänne, PA, Eberhardt, WE, et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 8 (2013), 373–384.
143. 144 Paz-Ares, L, Mezger, J, Ciuleanu, TE, et al., the INSPIRE investigators. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 16 (2015), 328–337.
144. 145 Paz-Ares, L, Socinski, MA, Shahidi, J, et al. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer. Ann Oncol 27 (2016), 1573–1579.
145. 146 Paz-Ares, L, Socinski, MA, Shahidi, J, et al. 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Thorac Oncol, 11, 2016, S153.
146. 147 Seto, T, Higashiyama, M, Funai, H, et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 53 (2006), 91–96.
147. 148 Postow, MA, Callahan, MK, Wolchok, JD, Immune checkpoint blockade in cancer therapy. J Clin Oncol 33 (2015), 1974–1982.
148. 149 Pennell, NA, Understanding the rationale for immunotherapy in non-small cell lung cancer. Semin Oncol 42:suppl 2 (2015), S3–10.
149. 150 Kim, MY, Koh, J, Kim, S, Go, H, Jeon, YK, Chung, DH, Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer 88 (2015), 24–33.
150. 151 Calles, A, Liao, X, Sholl, LM, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer. J Thorac Oncol 10 (2015), 1726–1735.
151. 152 Ma, W, Gilligan, BM, Yuan, J, Li, T, Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol, 9, 2016, 47.
152. 153 Gettinger, SN, Horn, L, Gandhi, L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
153. 154 Fehrenbacher, L, Spira, A, Ballinger, M, et al., the POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
154. 155 Rizvi, NA, Brahmer, JR, Ou, SHI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol, 33(suppl), 2015, 8032 (abstr).
155. 156 Antonia, S, Goldberg, SB, Balmanoukian, A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17 (2016), 299–308.
156. 157 Merck's KEYTRUDA (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer. http://investors.merck.com/investors/financial-news/press-release-details/2016/Mercks-KEYTRUDApembrolizumab-Demonstrates-Superior-Progression-Free-and-Overall-Survival-Compared-to-Chemotherapy-as-First-Line-Treatment-in-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer/default.aspx (accessed Aug 17, 2016).
157. 158 Hellman, MD, Gettinger, SN, Goldman, JW, et al. CheckMate 012: safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced(adv) NSCLC. J Clin Oncol, 34(suppl), 2016, 3001 (abstr).
158. 159 Sharma, P, Allison, JP, The future of immune checkpoint therapy. Science 348 (2015), 56–61.
159. 44 Kim, HS, Mitsudomi, T, Soo, RA, Cho, BC, Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer 80 (2013), 249–255.